VYALEV

Growth

foscarbidopa/foslevodopa

AbbVie
NDASUBCUTANEOUSSOLUTION
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
Jun 10, 2040
173 months away
Patent Expiry
Jun 10, 2040
Exclusivity Expiry
Oct 16, 2027

Patent Records (4)

Patent #ExpiryTypeUse Code
10174061
Oct 21, 2035
Product
U-4030
10730895
Oct 21, 2035
Substance
—
9446059
Oct 21, 2035
SubstanceProduct
U-4030
12251365
Jun 10, 2040
U-4030
Company
AbbVie
AbbVie
NORTH CHICAGO, IL
1495 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers